retatrutide available Lilly Prepares for FDA Filing Following Additional Phase 3 Data in Diabetes, CVD Demand for Unapproved Weight-Loss Drug

GLP-1 RA use is associated with a greater but moderate reduction in HbA 1c and lower risk of DKA when compared with SGLT2i therapy

10.1016/j.cell.2022.02.011 4 ApovianC

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved trial

And the inference runs both ways in a harmful direction: assuming that visible weight loss must be pharmacological dismisses people who achieved it otherwise, and assuming it must not be dismisses the legitimacy of the treatment

Teach the proper technique, and check their technique at follow-up visits

Insulin sensitivity improvements accompany the direct glucose-lowering effects